In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Cambridge Antibody to develop therapeutic MAbs for HGS

Executive Summary

In exchange for research funding, plus potential milestones and sales royalties, Cambridge Antibody Technology will provide its high-throughput isolation technologies to develop fully human monoclonal antibodies (MAbs) for up to three human proteins from Human Genome Sciences' targets. The two biotechs will focus on a specific fast-track antigen that HGS discovered through its genomics program.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Genomics-Proteomics
      • Molecular Diversity
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies